CV Sciences Certificate of Analysis



This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.

SAMPLE ID:	PRODUCT NAME:
Strength:	
Lot Number:	
Expiration Date:	

CANNABINOIDS*	MG/UNIT	METHOD
CBD		
CBDA		
d9-THC		
THCA-A		
d8-THC		
ТНСV		
CBDV		
CBDVA		
CBGA		
CBG		
CBN		
CBC		
CBL		
Total Cannabinoids		
Sample Size		
THC by Mass		

HEAVY METALS*	STATUS (PASS/FAIL)	METHOD
Arsenic		
Cadmium		
Mercury		
Lead		

Docusign Envelope ID: E514B157-7655-432F-8A84-AB0075FE9C5F

CV Sciences Certificate of Analysis



-			
	MICROBIOLOGY*	STATUS (PASS/FAIL)	METHOD
	Mold/Mildew/Yeast		
	Aerobic Bacteria		
	Coliforms		
	E. Coli		
	Salmonella		
	Pseudomonas		

PESTICIDES**	STATUS (PASS/FAIL)	METHOD
Total Pesticides		
Mycotoxins	Pass	
RESIDUAL SOLVENTS**	STATUS (PASS/FAIL)	METHOD
Total Residual Solvents		

- 1. The hemp extract is the product of a batch tested by the independent testing laboratory;
- 2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
- 3. The batch does not contain contaminants unsafe for human consumption.⁺

[†]Tested analytes and limits were set by CV Sciences, Inc.

DB Labs Sample ID #:

*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.

Anresco Laboratories Sample ID #:

**Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.





CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126

Certificate of Analysis

Order No. 561187 Sample No. 1245256

SAMPLE INFORMATION

Description	FP-24-0089 PlusCBD 50mg 60ct Softgels exp 08/26 SKU 391
Lot Number	A107360924
Category (Type)	Non-Inhalable Edible (Capsule)
Received	September 20, 2024

ANALYTICAL RESULTS

Analysis	Cannabinoid Profile (Non-Plant) 🛛 🔮 Pass
Instrument	Liquid Chromatography Diode Array Detector (LC-DAD)
Method	MF-CHEM-15
Analysis Date	September 20, 2024

Cannabinoid	mg/g	%	mg/serving	mg/package	Labeled mg/ serving	% Difference (mg/ serving)	Status
Δ8-THC	ND	ND	ND	ND	-	-	-
Δ9-THC	ND	ND	ND	ND	-	-	Pass
Δ9-THCA	ND	ND	ND	ND	-	-	-
THCV	ND	ND	ND	ND	-	-	-
THCVA	ND	ND	ND	ND	-	-	-
CBD	84.98	8.498	53.86	3231.8	50	7.73	-
CBDA	ND	ND	ND	ND	-	-	-
CBC	2.35	0.235	1.49	89.30	-	-	-
CBCA	ND	ND	ND	ND	-	-	-
CBDV	1.48	0.148	0.94	56.38	-	-	-
CBG	1.95	0.195	1.24	74.17	-	-	-
CBGA	ND	ND	ND	ND	-	-	-
CBN	2.80	0.280	1.78	106.60	-	-	-
Total THC	ND	ND	ND	ND	-	-	-
Total CBD	84.98	8.498	53.86	3231.8	-	-	-
Total Cannabinoids	93.57	9.357	59.30	3558.26	-	-	-
Sum of Cannabinoids	93.57	9.357	59.30	3558.26	-	-	-
Serving Weight (g)	0.6338						
Package Weight (g)	38.03						

Comments

Reported by Anresco, Inc.



September 20, 2024

Reported results and measurements are based off of a calculated hypothetical weight using the ratio between filling weight and total capsule weight as per client instruction. Only the filling material was tested.

ND = None Detected LOD = Limit of Detection (0.1333 mg/g) LOQ = Limit of Quantitation (0.4000 mg/g) Total THC = $\Delta 8$ -THC + $\Delta 9$ -THC + (0.877 * THCA) Total CBD = CBD + (0.877 * CBDA) Total Cannabinoids = Σ (neutral cannabinoids) + [0.877 * Σ (acidic cannabinoids)]

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 Sample #: 1245256 Batch #: A107360924 page **1** of **1** Report ID: T-2



CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126 **Certificate of Analysis**

Order No. 561187 Sample No. 1245256

SAMPLE INFORMATION

Description	FP-24-0089 PlusCBD 50mg 60ct Softgels exp 08/26 SKU 391
Lot Number	A107360924
Category (Type)	Non-Inhalable Edible (Capsule)
Received	September 20, 2024

ANALYTICAL RESULTS

Analysis	Pesticide Screen 🔮 Pass
Instrument	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method	MF-CHEM-13
Analysis Date	September 20, 2024 to September 24, 2024

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.017/0.05	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.017/0.05	ND	0.017	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.06	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.017/0.05	ND	0.017	Pass
DDVP (Dichlorvos)	0.013/0.04	ND	0.013	Pass
Diazinon	0.017/0.05	ND	0.2	Pass
Dimethoate	0.017/0.05	ND	0.017	Pass
Dimethomorph	0.017/0.05	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.017/0.05	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratorieswww.anresco.comSample#: 1245256page 1 of 21375 Van Dyke Ave., San Francisco, CA 94124Batch #: A107360924Report ID: T-2



Certificate of Analysis

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.017/0.05	ND	5.0	Pass
Metalaxyl	0.017/0.05	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.013/0.04	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.017/0.05	ND	0.5	Pass
Oxamyl	0.013/0.04	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.017/0.05	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.017/0.05	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.013/0.04	ND	0.013	Pass
Pyrethrins	0.15/0.50	ND	1.0	Pass
Pyridaben	0.017/0.05	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.017/0.05	ND	0.017	Pass
Tebuconazole	0.02/0.06	ND	2.0	Pass
Thiacloprid	0.013/0.04	ND	0.013	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	ND	30.0	Pass

Reported by **Anresco, Inc.**



September 24, 2024

ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124



CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126 **Certificate of Analysis**

Order No. 561187 Sample No. 1245256

SAMPLE INFORMATION

Description	FP-24-0089 PlusCBD 50mg 60ct Softgels exp 08/26 SKU 391
Lot Number	A107360924
Category (Type)	Non-Inhalable Edible (Capsule)
Received	September 20, 2024

ANALYTICAL RESULTS

Analysis	Residual Solvent Screen 🛛 🔮 Pass
Instrument	Gas Chromatography Mass Spectrometry (GC/MS)
Method	MF-CHEM-32
Analysis Date	September 20, 2024 to September 24, 2024

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.5/0.5	ND	1	Pass
Acetone	57/200	ND	5000	Pass
Acetonitrile	56/200	ND	410	Pass
Benzene	0.5/0.5	ND	1	Pass
n-Butane	45/200	ND	5000	Pass
Chloroform	0.5/0.5	ND	1	Pass
Ethanol	37/200	ND	5000	Pass
Ethyl acetate	38/200	ND	5000	Pass
Ethyl ether	37/200	ND	5000	Pass
Ethylene oxide	0.1/0.5	ND	1	Pass
n-Heptane	135/200	ND	5000	Pass
n-Hexane	49/200	ND	290	Pass
Isopropyl alcohol	57/200	ND	5000	Pass
Methanol	37/200	ND	3000	Pass
Methylene chloride	0.1/0.5	ND	1	Pass
n-Pentane	37/200	ND	5000	Pass
Propane	72/200	ND	5000	Pass
Toluene	49/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	58/200	ND	2170	Pass
Trichloroethylene	0.5/0.5	ND	1	Pass

Reported by Anresco, Inc.



September 24, 2024

ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 page **1** of **1** Report ID: T-2



CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126 **Certificate of Analysis**

Order No. 561187 Sample No. 1245256

SAMPLE INFORMATION

Description	FP-24-0089 PlusCBD 50mg 60ct Softgels exp 08/26 SKU 391	
Lot Number	A107360924	
Category (Type)	Non-Inhalable Edible (Capsule)	
Received	September 20, 2024	
	ANALYTICAL RESULTS	

Analysis	Mycotoxins Screen 🔮 Pass
Instrument	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method	MF-CHEM-13
Analysis Date	September 20, 2024 to September 24, 2024

Analyte	LOD/LOQ (ppb)	Findings (ppb)	Limit (ppb)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/18	ND	20	Pass

Reported by Anresco, Inc.

ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation



September 24, 2024

If there are any questions with this report, please contact "compliance@anresco.com".



CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126 Order No. 561187 Sample No. 1245256

Certificate of Analysis

SAMPLE INFORMATION

DescriptionFP-24-0089 PlusCBD 50mg 60ct Softgels exp 08/26 SKU 391Lot NumberA107360924ReceivedSeptember 20, 2024

ANALYTICAL RESULTS

Analysis Date September 20, 2024 to September 26, 2024

Findings	Analysis	Results	Method
	Standard Plate Count	<10 cfu/g	FDA BAM
	Yeast	<10 cfu/g	FDA BAM
	Mold	<10 cfu/g	FDA BAM
	Coliforms	<10 cfu/g	FDA BAM - ECC AGAR
	Escherichia coli	<10 cfu/g	FDA BAM - ECC AGAR
	Salmonella	Negative /10g	MF-MICRO-11 (AOAC 2016.01)
	Staph aureus	Negative /10g	USP <62>

Reported by **Anresco, Inc.**



If there are any questions with this report, please contact "compliance@anresco.com".

Tel: 415 822 1100 Fax: 415 822 6615 Report ID: S-1

page 1 of 1

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.



CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126

Order No. 561187 Sample No. 1245256

Certificate of Analysis

SAMPLE INFORMATION

Description	FP-24-0089 PlusCBD 50mg 60ct Softgels exp 08/26 SKU 391
Lot Number	A107360924
Category (Type)	Non-Inhalable Edible (Capsule)
Received	September 20, 2024

ANALYTICAL RESULTS

Analysis	Heavy Metals 🔮 Pass	
Instrument	Inductively Coupled Plasma Mass Spectrometry (ICP-MS)	
Method	MF-CHEM-16	
Analysis Date	September 20, 2024 to September 24, 2024	

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.02/0.05	ND	1.5	Pass
Cadmium	0.02/0.05	ND	0.5	Pass
Mercury	0.02/0.05	ND	3	Pass
Lead	0.02/0.125	<loq< td=""><td>0.5</td><td>Pass</td></loq<>	0.5	Pass

Reported by **Anresco, Inc.**



September 24, 2024

ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124

DocuSign^{*}

		2000.g.
Certificate Of Completion		
Envelope Id: E514B1577655432F8A84AB0075F1 Subject: FP-24-0089 PlusCBD 50mg 60ct Softg Source Envelope:		Status: Completed
Document Pages: 9 Certificate Pages: 1 AutoNav: Enabled Envelopeld Stamping: Enabled Time Zone: (UTC-08:00) Pacific Time (US & Can	Signatures: 1 Initials: 0 ada)	Envelope Originator: Vandana Kothari vandana.kothari@cvsciences.com IP Address: 64.207.219.135
Record Tracking		
Status: Original 9/27/2024 11:07:17 AM	Holder: Vandana Kothari vandana.kothari@cvsciences.com	Location: DocuSign
Signer Events	Signature	Timestamp
Vandana Kothari vandana.kothari@cvsciences.com DIRECTOR OF QUALITY CV Sciences - Part 11 Security Level: Email, Account Authentication (Required) Electronic Record and Signature Disclosure: Not Offered via DocuSign	Vandana kolluari Signature Adoption: Pre-selected Style Signature ID: 87A410FF-F032-4873-8900-BEED0868E359 Using IP Address: 75.85.176.253 With Signing Authentication via DocuSign passwor With Signing Reasons (on each tab): I approve this document	Sent: 9/27/2024 11:07:55 AM Viewed: 9/27/2024 11:08:52 AM Signed: 9/27/2024 11:09:25 AM
In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp

Payment Events	Status	Timestamps
Completed	Security Checked	9/27/2024 11:09:25 AM
Signing Complete	Security Checked	9/27/2024 11:09:25 AM
Certified Delivered	Security Checked	9/27/2024 11:08:52 AM
Envelope Sent	Hashed/Encrypted	9/27/2024 11:07:55 AM
Envelope Summary Events	Status	Timestamps
Notary Events	Signature	Timestamp
Witness Events	Signature	Timestamp
Carbon Copy Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Editor Delivery Events	Status	Timestamp
In Person Signer Events	Signature	limestamp